Revenio Group Corporation: Revenio's Icare launches new product generation

Revenio Group Corporation, Stock Exchange Release, December 22, 2015 at 9.00

REVENIO'S ICARE LAUNCHES NEW PRODUCT GENERATION

Icare Finland Oy, a subsidiary of Revenio Group, will launch a new ic100 tonometer on the European markets in January, to replace the TA01i tonometer introduced to the markets in 2003. The company expects the new device gradually to replace the TA01i in the markets. Around 50,000 Icare tonometers have been sold since 2003.

The Icare ic100 tonometer has already been awarded a CE mark for the European markets, gaining relevant sales permit for all EU countries. The company has reinforced its sales and marketing organization in preparation for sales of the new product generation. A sales license application is estimated to be submitted to the FDA in the US during Q1/2016.

In developing of the ic100 Icare tonometer, the focus has been in improving ergonomics, measurement of intraocular pressure and modern design. Icare® AMS, a familiar feature of the Icare HOME tonometer, allows a series of six measurements at a single touch of a button. Based on a green and red light, Icare® EasyPos guides the tonometer into the correct position, while the Icare® EasyNav interface and a large color screen make the device easy to use.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The Revenio Group comprises the business operations of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis screening and monitoring. In addition, Revenio has identified new growth opportunities relating to health tech in which common denominators are screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating margin for continuing operations standing at 27.5%. Revenio Group Corporation has been listed in Nasdaq Helsinki.